Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Rettig

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET ImagingRichard Laforest, Anchal Ghai, Tyler J Fraum, et al.
Nature Communications|January 20, 2018
Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancerNalinikanth Kotagiri, Matthew L Cooper, Michael Rettig, et al.
Research Square|August 16, 2024
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialArmin Ghobadi, Ibrahim Aldoss, Shannon Maude, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Molecular Cancer Therapeutics|May 11, 2018
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and LeukemiaVanessa Buatois, Zoë Johnson, Susana Salgado-Pires, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET ImagingRichard Laforest, Anchal Ghai, Tyler J Fraum, et al.
Nature Communications|January 20, 2018
Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancerNalinikanth Kotagiri, Matthew L Cooper, Michael Rettig, et al.
Research Square|August 16, 2024
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialArmin Ghobadi, Ibrahim Aldoss, Shannon Maude, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Molecular Cancer Therapeutics|May 11, 2018
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and LeukemiaVanessa Buatois, Zoë Johnson, Susana Salgado-Pires, et al.
Pageof 4